|
To: Maine Immunization Program Providers
From: Maine Immunization Program
Subject: New ROTARIX® Formulation Available to Order
Date: March 13, 2023
On November 4, 2022, the FDA approved a new formulation of ROTARIX®. This new oral-dosing applicator-only presentation of Rotarix rotavirus vaccine, manufactured by GSK is now available to order through the Maine Immunization Program (MIP). The new liquid formulation does not require reconstitution.
Please review the Full Prescribing Information here for further details.
Effective immediately, all Rotarix orders will be switched to the new liquid formulation, and the lyophilized formulation will no longer be available to order.
The two vaccines currently licensed and available to order through MIP are the RotaTeq (Merck & Co) (RV5) and ROTARIX (GSK) (RV1). These vaccines are considered equally safe and effective and only differ in composition and schedule.
- RotaTeq® (RV5), is given in three doses at 2 months, 4 months, and 6 months of age.
- Rotarix® (RV1), is given in two doses at 2 months and 4 months of age.
The first dose of rotavirus vaccine should be given before a child is 15 weeks of age. Children should receive all doses of rotavirus vaccine before they turn 8 months of age.
For more information, please see the New Liquid Formulation ROTARIX Licensure FAQ | CDC.
Should you have additional questions, please contact the Maine Immunization Program at (207) 287-3746 or email ImmunizeME.DHHS@maine.gov.
Thank you for all you do to keep Maine children safe from vaccine preventable disease.
|
